Overland Pharmaceuticals Announces Presentations at ASGCT Annual Meeting for Novel Cell Therapies for Oncology and Autoimmune Diseases

South San Francisco, Calif., May 09, 2024 – Overland Pharmaceuticals (“Overland” or the “Company”), a global biotechnology company focused on oncology and autoimmune diseases, announced that two presentations are featured at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting in Baltimore, Maryland on May 7-11, 2024.

Overland is advancing two lead programs: OL-101, autologous GPRC5D and BCMA bispecific dual targeting CAR-T, and allogeneic γδ-T cell therapy platform for autoimmune diseases.

• OL-101 is a potentially best-in-class dual-targeting CAR-T for multiple myeloma that is on track for human clinical testing in the fourth quarter of 2024. Overland aims to target post-BCMA relapsed refractory multiple myeloma patients with the potential to move into earlier lines of therapy.
• Overland also aims to leverage its internally established allogeneic γδ-T cell therapy platform to address unmet medical needs in autoimmune diseases through potentially safer and more cost-effective off-the-shelf cell therapy treatments.

The company will provide an oral presentation on key preclinical data for OL-101, its novel VHH‐based GPRC5D and BCMA bispecific CAR product candidate, that demonstrates suppression of tumor growth in vitro and in vivo. In addition, Overland will present on the development of its proprietary allogeneic γδ-T platform with demonstrated CAR-mediated preclinical efficacy.

Presentation and poster details are as follows:

G Protein-Coupled Receptor Class C Group 5 Member D (GPRC5D) and B-Cell Maturation Antigen (BCMA) Bi-Specific Dual Chimeric Antigen Receptors (CARs) Effectively Address Antigen Escape and Tumor Heterogeneity Challenge in Multiple Myeloma (MM)
Abstract Number: 378
Session: Novel Immune Effector Cell Manufacturing
Location: Ballroom 2
Presentation Date / Time: May 11, 2024 at 11:30 AM EST

Development of A Novel Allogeneic γδ-T Platform for Off-the-shelf Adoptive Cell Therapy for Oncology and Autoimmune Diseases
Abstract Number: 1813
Session: Immune Targeting and Approaches with Genetically-Modified Cells and Cell Therapies
Location: Exhibit Hall
Presentation Date / Time: May 10, 2024 at 12:00 PM EST

About Overland Pharmaceuticals
Overland Pharmaceuticals is building a global biotechnology company with a mission to bring innovative medicines to underserved patients in Asia and around the world. By leveraging our resources, global network, and local expertise across the biopharma ecosystem in Asia, Overland is establishing a portfolio of differentiated therapeutic candidates in oncology and autoimmune diseases.

Media Contact
Michael Chen
ylchen@overlandpharma.com